Regional Hematology-Oncology Newark, DE - 19713

Regional Hematology-Oncology is categorized under Oncologists in Newark, DE .

Regional Hematology-Oncology was established in 0, and today employs 1 to 4, earning $5.000.000 to $9.999.999 per year. This is a Oncologists business, which does work in the B2C market, and is classified as a Oncologists, under code number 6211110 by the NAICS.

If you are seeking more information, feel free to contact Elizabeth Galante, Office Manager at the company’s single location by writing to 4701 Ogletown Stanton Road # 2400, Newark, Delaware DE 19713 or by phoning (302) 731-7782. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.

Business Name: Regional Hematology-Oncology
Contact Person: Elizabeth Galante, Office Manager
Address: 4701 Ogletown Stanton Road # 2400, Newark, Delaware 19713
Phone Number: (302) 731-7782
Website Address: rhopa.com
Annual Revenue (USD): $5.000.000 to $9.999.999
Location Type: Single Location
Employee Number: 1 to 4
Business Type: B2C (Business to Consumer)
Business Category: Oncologists
SIC Code: 8011
NAICS Code: 6211110
Share This Business:

Regional Hematology-Oncology was started in 0 to provide professional Oncologists under the SIC code 8011 and NAICS code 6211110. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $5.000.000 to $9.999.999 per annum.

Feel free to contact Elizabeth Galante, Office Manager for inquiries that concern Regional Hematology-Oncology by calling the company number (302) 731-7782, as your correspondence is most welcome. Additionally, the physical location of the single location of Regional Hematology-Oncology can be found at the coordinates 39.686655,-75.680018 as well as the street address 4701 Ogletown Stanton Road # 2400 in Newark, Delaware 19713.

For its online presence, you may visit Regional Hematology-Oncology’s website at rhopa.com and engage with its social media outlets through on Twitter and on Facebook.